ÂÜÀòÂÒÂ×

Ron Advanie currently serves as the Director of Value & Access Strategy and Innovation for Oncology at Boehringer Ingelheim, focusing on DLL-3 T-Cell Engager launch planning. Prior to this role, Ron held a similar director position in Immunology at Boehringer Ingelheim, overseeing the Spevigo launch. Ron's experience at Amgen includes senior managerial roles in Value Marketing for Immunology and Nephrology, as well as Coverage and Pricing for Neuroscience, significantly contributing to the launches of Enbrel, Otezla, Avsola, Parsabiv, Aranesp, and Aimovig. Earlier in the career, Ron worked as a Senior Analyst at Allergan, focusing on Payer Marketing and Provider Access Strategy for Botox and Ozurdex, and served in various analytical roles at Percepta Associates. Educational qualifications include a Master of Bioscience degree from Keck Graduate Institute and a Bachelor of Engineering degree in Biotechnology from the University of Mumbai.